Aim: This phase III, multicentre, randomized study (ClinicalTrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53-91 mmol/mol]) despite diet and exercise.
| INTRODUCTION
Inhibition of renal glucose reabsorption and reduction of the renal threshold for glucose excretion via inhibition of sodium-glucose cotransporter 2 (SGLT2) has been shown to improve glycaemic control in patients with type 2 diabetes mellitus (T2DM). SGLT2 inhibitors are the most recent class of oral anti-hyperglycaemic agent (AHA) approved for the treatment of this condition. 1, 2 Ertugliflozin is a highly selective SGLT2 inhibitor under clinical development for T2DM. In phase II studies in individuals with T2DM, ertugliflozin significantly reduced plasma glucose and glycated haemoglobin (HbA1c) levels, and showed beneficial effects on body weight and blood pressure.
3, 4 Results from phase III studies demonstrate that ertugliflozin provided clinically meaningful reductions from baseline in HbA1c, body weight and blood pressure through 26 weeks of treatment. [5] [6] [7] Several of these studies include controlled extension phases for the purpose of collecting longer-term efficacy and safety data.
The phase III VERTIS (eValuation of ERTugliflozin effIcacy and
Safety) MONO study (NCT01958671) was designed to assess the efficacy and safety of ertugliflozin monotherapy in participants with T2DM and inadequate glycaemic control despite diet and exercise.
The study comprised a 26-week, double-blind, placebo-controlled treatment period (Phase A), followed by a 26-week active-controlled treatment period (Phase B). We have previously reported the results from the Phase A treatment period, wherein ertugliflozin significantly improved glycaemic control and body weight after 26 weeks of treatment. 8 Here, we report efficacy and safety results through to study completion (Week 52; Phase A + B).
| MATERIALS AND METHODS
The study was conducted in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all
International Council on Harmonisation Good Clinical Practice Guidelines. The protocol was approved by institutional review boards or independent ethics committees, and written informed consent was obtained from all study participants. Participants were enrolled at 67 sites across 7 countries (USA, Canada, Israel, Italy, Mexico, South Africa and the UK).
| Key eligibility criteria
The eligibility criteria and study design have been published previously. 8 In brief, men and women aged ≥18 years, with a diagnosis of 
| Study design and treatment
The design of the trial is shown in Figure S1 . This was a double-blind, 
| Study endpoints
The primary objective of the Phase B portion of the trial was to assess the safety and tolerability of ertugliflozin through Week 52. All hypotheses were tested at Week 26. The secondary objectives were to assess the change from baseline to Week 52 in efficacy endpoints (see below). There were no formal hypothesis tests at Week 52.
| Efficacy assessments
A detailed description of efficacy assessments at Week 26 has been published previously. 8 Change from baseline to Week 52 was calculated for HbA1c, FPG, body weight and systolic and diastolic blood pressure (SBP; DBP). The proportion of participants with HbA1c <7.0% (53 mmol/mol) and with HbA1c <6.5% (48 mmol/mol) at Week 52 was assessed, as was the proportion of participants who received glycaemic rescue therapy.
| Safety assessments
A detailed description of safety assessments has been published previously. 8 Here mmol/L (70 mg/dL), with or without symptoms, was assessed.
Severe hypoglycaemia, defined as episodes that required the assistance of a third party, was also evaluated.
Prespecified events were subject to adjudication by an external panel of independent physicians, with medical expertise relevant to the event type, who were blinded to participant treatment. These Clinical Adjudication Committees (CACs) evaluated cardiovascular events and all-cause deaths, fractures, pancreatitis, renal and hepatic events. Potential cases of ketoacidosis were reviewed by an internal blinded case review committee. Adjudication results from the cardiovascular committee will be reported separately as part of a programme-wide summary.
| Statistical analyses
The population for Phase A + B descriptive efficacy analyses included all randomized participants who received ≥1 dose of study medication and who had baseline data and ≥1 post-randomization observation for the analysis endpoint subsequent to ≥1 dose of study treatment.
Because of the use of metformin in Phase B, no formal efficacy comparisons between the ertugliflozin and placebo/metformin groups were made at Week 52, and raw mean changes from baseline are presented.
Change from baseline in endpoints at Week 52 were also assessed, using a longitudinal data analysis (LDA) model 9 for the ertugliflozin groups. Least squares (LS) mean change from baseline is presented from this analysis, which is consistent with the type conducted at Week 26, the results of which have been reported previously. 8 Efficacy endpoints were summarized using the "excluding rescue approach": efficacy data obtained after the initiation of glycaemic rescue therapy were censored (ie, treated as missing) to avoid confounding. The observed proportion of patients with HbA1c <7.0% (53 mmol/mol) and with HbA1c <6.5% (48 mmol/mol) at Week 52 was assessed.
The population for Phase A + B safety analyses included all randomized participants who received ≥1 dose of study medication, and included all data from randomization up to 14 days after the final dose of study medication for AEs and 2 days for laboratory parameters.
With the exception of hypoglycaemia, safety analyses were conducted using the "including rescue approach." GMIs (by gender), UTIs, symptomatic hypoglycaemia and hypovolaemia AEs ("Tier 1 AEs") were subject to inferential testing without multiplicity control, for which P values and 95% CIs for between-treatment differences were provided, using the Miettinen and Nurminen method. 10 The term "significantly" higher or lower has been used when the P value was <.05.
Other safety results have been described as "higher" or "lower" as part of a qualitative assessment only. Percent changes from baseline in lowdensity lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were analysed using a LDA model, which included terms for treatment, time, treatment by time interaction, prior antihyperglycaemic medication (yes, no) and baseline eGFR (continuous).
3 | RESULTS
| Participant disposition and baseline characteristics
In Phase A, 461 participants were randomized and received ≥1 dose of study medication. A total of 384 participants entered and received ≥1 dose of study medication in Phase B (Figures S2 and S3 ). Baseline demographics and clinical characteristics for the Phase A + B treatment period were similar across treatment groups (Table S1) 
| Efficacy outcomes
Reductions from baseline in HbA1c were observed in both ertugliflo- Table S2 . These results are consistent with the change from baseline in raw means at Week 52.
| Safety outcomes 3.3.1 | Overall safety
The overall incidence of AEs, serious AEs (SAEs) and drug-related AEs was similar between the ertugliflozin and placebo/metformin groups ( Table 1 ). The incidences of AEs leading to discontinuation of study medication were not notably different across treatment groups (placebo/metformin, 6.5%; ertugliflozin 5 mg, 4.5%; ertugliflozin 15 mg, 3.9%). The most commonly reported drug-related AEs in the ertugliflozin groups were associated with GMIs; the AEs with the highest incidence in the ertugliflozin groups were vulvovaginal candidiasis and vulvovaginal mycotic infection. The incidence of drug-related AEs in Phase B was lower in the ertugliflozin groups compared with the placebo/metformin group, and was largely the result of an increased incidence of gastrointestinal-related AEs in Phase B in the placebo/metformin group. There was 1 death (ruptured cerebral aneurysm), which occurred in a participant in the ertugliflozin 5 mg group on Day 362, and which the investigator assessed as not related to study medication.
| "Tier 1" and other adverse events
Over 52 weeks, the incidence of GMIs in women was significantly higher in the ertugliflozin 5 mg (26.9%; P = .010) and ertugliflozin 15 mg (29.0%; P = .005) groups compared with the placebo/metformin (9.9%) group (Figure 3) . GMI AEs led to discontinuation of study medication in 3 female participants (2, ertugliflozin 15 mg; 1, ertugliflozin 5 mg). In men, the incidence of GMIs was higher in the ertugli- 
| Laboratory parameters
Changes from baseline at Week 52 in LDL-C, HDL-C and LDL-C:
HDL-C ratio are shown in Table S3 . At Week 52, eGFR was similar to A summary of key laboratory data is provided in Table S4 . Small mean increases from baseline in both magnesium and phosphate were observed in the ertugliflozin groups at Week 26; however, there was no further increase through Week 52. Small mean decreases in uric acid from baseline at Week 52 were observed in both ertugliflozin groups. Mean decreases in ALT and AST were observed in all treatment groups at Week 52. Mean increases from baseline in haemoglobin and haematocrit levels were observed through Week 52 in both ertugliflozin groups.
| DISCUSSION
The min is in line with prior studies in which the same dose was used. 13 Although this study was not powered for a formal comparison of the with metformin at 24 weeks. 14 Similarly, in a head-to-head study of metformin vs dulaglutide, a 2.2 kg weight loss was observed at 26 weeks in patients who received metformin. 15 Ertugliflozin was generally well tolerated throughout the 52-week treatment period in this study population. The overall incidences of AEs, SAEs and AEs leading to discontinuation of study medication were similar across treatment groups. The incidence of GMIs was higher in the ertugliflozin groups compared with the placebo/metformin group, but there was no increased incidence of UTI, symptomatic hypoglycaemia or hypovolaemia AEs. Similar to reports for other SGLT2 inhibitors, the majority of GMI events occurred early in the study. 16, 17 There was no increase in AEs associated with osmotic diuresis.
Initial mean reductions in eGFR in the ertugliflozin groups at Ertugliflozin, administered to adults with inadequately controlled T2DM despite diet and exercise, improved glycaemic control and reduced body weight and SBP. Both doses provided a clinically meaningful reduction from baseline in HbA1c that was maintained over 52 weeks. There was no increase in the incidence of symptomatic hypoglycaemia, UTI or hypovolaemia AEs with ertugliflozin, but the incidence of GMIs was higher compared with placebo/metformin.
